Jade Biosciences
Clinical-stage biotechnology company developing monoclonal antibody therapies for autoimmune diseases. Lead APRIL-targeting antibody is planned to enter first-in-human studies in the second half of 2025. Company activities described in source materials include antibody engineering (including afucosylation and half-life extension), preclinical non-human primate pharmacology, biomarker-driven PK/PD evaluation, regulated clinical development, regulatory planning for registrational trials, and corporate financing and public listing following a reverse merger and private placement.
Industries
Nr. of Employees
small (1-50)
Jade Biosciences
Waltham, Massachusetts, United States, North America
Products
JADE101
Investigational fully human monoclonal antibody that blocks APRIL to reduce pathogenic IgA; engineered for extended half-life and subcutaneous dosing intervals intended to be at least eight weeks. Advancing from IND-enabling studies toward first-in-human clinical evaluation.
JADE201
Development candidate arising from an internal antibody discovery program with Fc-engineering to enhance effector function and extend half-life; intended to modulate BAFF-R–expressing B cells and deplete pathogenic B cells across autoimmune indications.
Preclinical antibody discovery programs (JADE-002 / JADE-003)
Undisclosed optimized antibody discovery programs in preclinical development to broaden pipeline targeting immune pathways.
JADE-002
JADE-002 is a clinical-stage anti-APRIL monoclonal antibody developed by Jade Biosciences for the treatment of IgA nephropathy (IgAN).
JADE-003
An undisclosed development candidate licensed from Paragon Therapeutics, planned for clinical trials in 1H27.
JADE301
JADE301 is a half-life–extended anti-IFN-β monoclonal antibody in development for dermatomyositis, a rare and debilitating autoimmune disease in which excessive IFN-β activity is believed to be the central driver of muscle and skin pathology.
JADE101
Investigational fully human monoclonal antibody that blocks APRIL to reduce pathogenic IgA; engineered for extended half-life and subcutaneous dosing intervals intended to be at least eight weeks. Advancing from IND-enabling studies toward first-in-human clinical evaluation.
JADE201
Development candidate arising from an internal antibody discovery program with Fc-engineering to enhance effector function and extend half-life; intended to modulate BAFF-R–expressing B cells and deplete pathogenic B cells across autoimmune indications.
Preclinical antibody discovery programs (JADE-002 / JADE-003)
Undisclosed optimized antibody discovery programs in preclinical development to broaden pipeline targeting immune pathways.
JADE-002
JADE-002 is a clinical-stage anti-APRIL monoclonal antibody developed by Jade Biosciences for the treatment of IgA nephropathy (IgAN).
JADE-003
An undisclosed development candidate licensed from Paragon Therapeutics, planned for clinical trials in 1H27.
JADE301
JADE301 is a half-life–extended anti-IFN-β monoclonal antibody in development for dermatomyositis, a rare and debilitating autoimmune disease in which excessive IFN-β activity is believed to be the central driver of muscle and skin pathology.
Expertise Areas
- Clinical trial management
- PK/PD modelling and dose regimen optimization
- Biomarker-driven translational medicine
- Antibody engineering and biologics design
Key Technologies
- Monoclonal antibody therapeutics
- Fc engineering (afucosylation) and effector function modulation
- Half-life extension technologies
- Subcutaneous biologic delivery
News & Updates
Company completed reverse merger with Aerovate Therapeutics and the combined company began trading on Nasdaq under the ticker JBIO; transaction closed with private placement proceeds.
Management participated in TD Cowen’s Annual Health Care Conference (March 3-5, 2025) and Jefferies Biotech on the Beach Summit (March 11-12, 2025) and offered one-on-one investor meetings.
Company presentation scheduled at the Jefferies Global Healthcare Conference, June 3-5, 2025, with CEO presenting on June 4, 2025.
Quarterly financial results announced including cash position, operating expense breakdown and corporate updates noting completed reverse merger, private financing, and pipeline status (lead candidate anticipated to enter clinic in H2 2025).
Management presentations and investor meetings at Stifel 2024 Healthcare Conference and Jefferies London Healthcare Conference; archived webcasts made available to investors.
Company announced $80 million financing to support development of autoimmune therapies and named Chief Scientific Officer; financing led by institutional healthcare investors.
Company completed reverse merger with Aerovate Therapeutics and the combined company began trading on Nasdaq under the ticker JBIO; transaction closed with private placement proceeds.
Management participated in TD Cowen’s Annual Health Care Conference (March 3-5, 2025) and Jefferies Biotech on the Beach Summit (March 11-12, 2025) and offered one-on-one investor meetings.
Company presentation scheduled at the Jefferies Global Healthcare Conference, June 3-5, 2025, with CEO presenting on June 4, 2025.
Quarterly financial results announced including cash position, operating expense breakdown and corporate updates noting completed reverse merger, private financing, and pipeline status (lead candidate anticipated to enter clinic in H2 2025).
Management presentations and investor meetings at Stifel 2024 Healthcare Conference and Jefferies London Healthcare Conference; archived webcasts made available to investors.
Company announced $80 million financing to support development of autoimmune therapies and named Chief Scientific Officer; financing led by institutional healthcare investors.